Hyperthyroidism in mice is associated with low bone mass, high bone turnover, and high concentrations of sclerostin, a potent Wnt inhibitor. Here, we explored the effects of either increasing bone formation with sclerostin antibodies (Scl-Ab) or reducing bone turnover with bisphosphonates on bone mass and strength in hyperthyroid mice. Twelve-week-old C57BL/6 male mice were rendered hyperthyroid using L-thyroxine (T4; 1.2 mg/mL added to the drinking water) and treated with 20 mg/kg Scl-Ab twice weekly or 100 mg/kg zoledronic acid (ZOL) once weekly or phosphatebuffered saline for 4 weeks. Hyperthyroid mice displayed a lower trabecular bone volume at the spine (242%, P , 0.05) and the distal femur (255%, P , 0.05) compared with euthyroid controls. SclAb and ZOL treatment of hyperthyroid mice increased trabecular bone volume at the spine by threefold and twofold, respectively. Serum bone formation and resorption markers were increased in hyperthyroid mice and suppressed by treatment with ZOL but not Scl-Ab. Trabecular bone stiffness at the lumbar vertebra was 63% lower in hyperthyroid mice (P , 0.05) and was increased fourfold by Sci-Ab (P , 0.001) and threefold by ZOL treatment (P , 0.01). Bone strength based on ultimate load, which was 10% lower in hyperthyroidism, was increased by Scl-Ab by 71% and ZOL by 22% (both P , 0.001). Increased proportion of low mineralized bone seen in hyperthyroid mice was restored by treatment with Scl-Ab and ZOL. Thus, bone-forming and antiresorptive drugs prevent bone loss in hyperthyroid mice via different mechanisms. (Endocrinology 158: 3765-3777, 2017) T he excessive production of thyroid hormones by the thyroid gland has distinct effects on the skeleton during bone modeling and remodeling (1). Although hyperthyroidism in children enhances skeletal development and leads to rapid growth, it finally results in short stature due to premature closure of growth plates (2). In adulthood, both overt and subclinical hyperthyroidism are linked to an increased bone turnover, a reduced bone mineral density (BMD), and are a predisposing factor for osteoporotic fractures (3, 4). These observations
T he excessive production of thyroid hormones by the thyroid gland has distinct effects on the skeleton during bone modeling and remodeling (1) . Although hyperthyroidism in children enhances skeletal development and leads to rapid growth, it finally results in short stature due to premature closure of growth plates (2) . In adulthood, both overt and subclinical hyperthyroidism are linked to an increased bone turnover, a reduced bone mineral density (BMD), and are a predisposing factor for osteoporotic fractures (3, 4) . These observations underline the fact that, although thyroid hormone excess activates osteoblast and osteoclast functions, the stimulating effect on osteoclasts prevails under chronic hyperthyroid conditions, leading to a state of high bone turnover and subsequent bone loss. However, the exact mechanisms through which thyroid hormones exert their actions on bone homeostasis are only partially unraveled.
Most actions of the thyroid hormones L-thyroxine (T4) and 3, 5, 3 0 -triiodo-L-thyronine (T3) are mediated by the nuclear thyroid hormone receptor (TR)a and TRb, which are expressed in chondrocytes, osteoblasts, and osteoclasts (5) (6) (7) . Thyroid hormones stimulate chondrocyte differentiation and apoptosis, whereas they inhibit proliferation and thus contribute to endochondral ossification (8) . In vivo, thyroid hormones lead to a drastic increase in osteoclast number and activity. The mechanisms of action, however, are not -well-defined, and it is unclear whether this is due to a direct effect on osteoclasts, an indirect effect through upregulation of receptor activator of nuclear factor kB-ligand and inhibition of osteoprotegerin in osteoblasts and osteocytes, or even due to rapid, nonclassical TR-independent actions of thyroid hormones (9) (10) (11) (12) . Studies with osteoblasts, alternatively, are very consistent in showing differentiationpromoting effects of thyroid hormones in vivo and in vitro, which is paralleled by a pronounced increase in the expression of type I collagen, alkaline phosphatase, and osteocalcin (13) (14) (15) . Previous studies indicate a role for Wnt signaling in this process. Using a TRb-mutated mouse model, O'Shea et al. (16) showed that elevated thyroid hormone concentrations lead to advanced ossification through activation of the Wnt pathway. Two potent inhibitors of Wnt signaling, however, were differentially regulated in a mouse model of exogenous hyperthyroidism with low bone mass showing high serum concentrations of sclerostin and low concentrations of dickkopf-1 (DKK-1) (17) . Serum sclerostin was further shown to decrease in hyperthyroid patients after treatment with the antithyroid drug methimazole (18) . As a monoclonal antibody against sclerostin has been proven effective in preventing bone loss and fractures in postmenopausal women (19, 20) , we assessed its efficacy to increase bone formation and ameliorate bone loss in a mouse model of hyperthyroidism. Additionally, we compared its effects to those of a bisphosphonate, which reduces bone turnover, to determine whether both treatment modalities are equally potent to maintain bone mass and bone strength in hyperthyroidism.
Materials and Methods

Animals
All animal procedures were approved by the Institutional Animal Care Committee of the Technische Universität Dresden and the Landesdirektion Dresden. Twelve-week-old male C57BL/6 mice were purchased from Janvier (Saint Berthevin, France) and housed under institutional guidelines. All mice (n = 50) were fed a standard diet, held in groups of five with 12-hour light/12-hour dark cycles, and received a cardboard house for cage enrichment purposes. Welfare of mice was controlled daily. Hyperthyroidism was induced as described (21) . Briefly, mice were randomized into two groups with 20 and 30 mice each (for the control and hyperthyroid group, respectively). Mice were rendered hyperthyroid by adding T4 (Sigma-Aldrich, Munich, Germany) to the drinking water (1.2 mg/mL) for 4 weeks. To that end, T4 was dissolved in water with NaOH at a concentration of 6 mg/mL. The final concentration of NaOH in the drinking water was 6 3 10 27 N and did not change the pH of the water. This stock solution (40 mL) was then diluted into 200 mL of tap water. The T4-containing drinking water was prepared fresh twice per week and kept protected from light. Euthyroid mice received tap water. All animals had ad libitum access to their diet and respective drinking water. Concomitantly, all mice (control, hyperthyroid) received intraperitoneal injections of either 20 mg/kg monoclonal sclerostin antibodies [Scl-Ab; kindly provided by Amgen (Thousand Oaks, CA) and UCB (Brussels, Belgium)] twice weekly (n = 5 per category) or 100 mg/kg zoledronic acid (ZOL) (Novartis, Basel, Switzerland) once weekly (n = 5 per category) or phosphate-buffered saline (PBS; vehicle control) (n = 5 per category) for four weeks. Hyperthyroid mice drank more water than euthyroid controls (4.4 mL per mouse per day vs T4, 6.2 mL per mouse per day). Treatment with Scl-Ab or ZOL reduced the increased water intake, although not significantly (Scl-Ab, 5.1 mL per mouse per day; ZOL, 5.0 mL per mouse per day). The experiment was performed twice, whereby at the second experiment euthyroid mice received only PBS intraperitoneal injections (n = 5), and hyperthyroid mice received either PBS or Scl-Ab or ZOL (n = 5 per category). After 4 weeks, mice were euthanized using an overdose of a ketamine (100 mg/kg body weight)/xylazine solution (10 mg/kg body weight). Blood was collected by heart puncture of anesthetized mice, and bones were collected after cervical dislocation. All subsequent analysis [microcomputed tomography (micro-CT) analysis, bone histomorphometry, quantitative backscatter electron imaging, serum analysis] were performed by technicians in a blinded fashion.
Micro-CT analyses
Analyses of the fourth lumbar vertebra, distal femur, and femoral shaft were performed with a vivaCT 40 (Scanco Medical, Brüttisellen, Switzerland) with an X-ray energy of 70 kVp (114 mA, 200 ms integration time) and an isotropic voxel size of 10.5 mm. All trabecular bone parameters at the vertebral body and distal femur [trabecular BMD, bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N)] as well as the structure model index (SMI) were calculated from 100 slices using the Scanco bone evaluation software. Cortical bone parameters (cortical BMD and cortical thickness) were calculated from 100 slices at the femoral midshaft using the cortical bone evaluation program from Scanco. Bone stiffness was calculated by a high-friction compression test in z-direction on the trabecular bone compartment of the fourth lumbar vertebra using finite element modeling by the Scanco FE software [problem 33 (high-friction compression test in the z-direction); mechanical parameter 42 (von Mises equivalent test)]. Results are presented according to the American Society for Bone and Mineral Research guidelines (22) .
Reference-point indentation and biomechanical testing
The samples were removed from ethanol and rehydrated in PBS for 24 hours prior to reference point indentation and mechanical testing as has been previously described (23) . Reference point indentation was performed with a BioDent machine (Active Life Scientific, Santa Barbara, CA). Briefly, three indents were made at three different sites of the femur using a series of five testing cycles at 2 N and 2 Hz. The data within each location were averaged to get a single representative value of one femur.
For the 3-point bending test of the same femur, the specimens were loaded at a rate of 0.05 mm/s to a preload of 2 N and held for 5 seconds before being loaded at a rate of 0.5 mm/s to failure (Zwick Roell, Ulm, Germany). Extrinsic parameters of bone tissue biomechanics such as stiffness, ultimate load, and energy to failure were subsequently determined for each sample using the raw load displacement curves.
Bone histomorphometry
Dynamic bone histomorphometry was performed as described previously (24) . Briefly, 5 and 2 days before euthanasia, all mice received two intraperitoneal injections of the fluorescent label calcein (20 mg/kg; Sigma-Aldrich). Bones from the third lumbar vertebra and proximal tibia were fixed in 4% PBSbuffered paraformaldehyde and dehydrated with 80% ethanol. Subsequently, the tibia and third vertebral body were embedded in methylmethacrylate and either cut into 7-mm sections to analyze calcein labels (fluorescence) or 4 mm for the different staining. The sections were stained with von Kossa and toluidine blue to analyze BV/TV, Tb.N, Tb.Sp, and Tb.Th. Fluorescence microscopy was applied to determine the mineralized surface/ bone surface, the mineral apposition rate, and the bone formation rate/bone surface.
Tartrate-resistant acid phosphatase (TRAP) staining was used to assess the number of osteoclasts per total area, osteoclast surface per bone surface, and number of osteoclasts per bone perimeter on paraffin sections from the distal femur and fourth lumbar vertebrae. Before embedding in paraffin, bones were fixed in 4% PBS-buffered paraformaldehyde, decalcified in Osteosoft (Merck, Darmstadt, Germany) for a week, and dehydrated using an ascending ethanol series. Sections with 2-mm thickness were prepared for staining. Histomorphometric analysis was performed with the Osteomeasure software (OsteoMetrics, Decatur, GA) according to international standards (25) .
Quantitative backscatter electron imaging analyses
Vertebral trabecular bone from the remaining embedded block samples was analyzed for bone mineralization density distribution (BMDD) based on quantitative backscatter electron imaging as described previously (26) . Images of bone areas of interest were acquired using a digital scanning electron microscope equipped with a four-quadrant semiconductor backscatter electron detector (Zeiss Supra 40; Zeiss, Oberkochen, Germany) at 3130 nominal magnification resulting in a pixel resolution of 0.9 mm per pixel. The operating voltage of the electron beam was set to 20 keV and the acquisition time per image was 100 seconds. The gray levels in the digital images correspond to the differences in intensities of the backscatter electron signal, which are dependent on the local calcium concentrations in the bone sample. Thus, the gray-level histogram of calibrated images can be transformed into calcium weight percentage histograms (so-called BMDD) (26) . For statistical comparison between different samples, five parameters were derived from each BMDD curve: the mean calcium concentration (Ca Mean ; weighted mean), the most frequently occurring calcium concentration (Ca Peak ; the peak position of the BMDD) in the sample, the width of the BMDD (Ca Width ; full width at half maximum) reflecting the heterogeneity in matrix mineralization, the portion of low mineralized bone (Ca Low ; the percentage of bone area mineralized ,17.68 weight percentage calcium, corresponding to bone matrix of primary mineralization), and the portion of highly mineralized bone (Ca High ; the percentage of bone area mineralized .95th percentile of the control BMDD).
Serum measurements
Serum concentrations of the bone formation markers N-terminal propeptide of type I procollagen (P1NP) and osteocalcin (OCN), as well as the bone resorption marker type I collagen cross-linked C-telopeptide (CTX; Ratlaps), were measured using enzyme-linked immunosorbent assays (ELISAs) from IDS (Frankfurt/Main, Germany) according to the manufacturer's protocol. Serum concentrations of the Wnt inhibitors DKK-1 (R&D Systems, Wiesbaden-Nordenstadt, Germany) and sclerostin (Alpco, Salem, NH) were measured using ELISAs. To assure successful experimental induction of hyperthyroidism, serum total T4 and total T3 concentrations were measured at the end of the study using radioimmunoassays (RIA-4524 and RIA-4525, respectively; DRG Instruments, Marburg, Germany) (17) . The bound radiolabeled tracer was counted in a gamma counter (1277 Gammamaster; LKB Wallac, Turku, Finland). The limit of quantification was 10 nM and 0.22 nM for T4 and T3, respectively. Intra-assay coefficients of variation were ,7.5%.
Statistical analysis
Results are presented as mean 6 standard deviation. Normality of the data was tested with the Kolmogorov-Smirnov test. Statistical analysis was performed using a one-way (for four groups) or two-way analysis of variance (for six groups) followed by a Bonferroni or Sidak multiple comparison post hoc test to detect differences within the treatment groups in Graphpad Prism 5 (GraphPad, La Jolla, CA). For the BMDD data, correlation analysis with all BMDD parameters except Ca High was based on Pearson product moment correlation. Ca High (of all study groups) failed normality, and therefore its relationship to histomorphometric parameters was analyzed using a Spearman rank order correlation.
Results
Hyperthyroidism was confirmed by the measurement of serum total T4 and total T3 concentrations at the end of the study. Serum T4 concentrations were 61 6 10 nM for euthyroid and 167 6 47 nM (P , 0.001) for hyperthyroid mice. Serum T3 concentrations were 1.42 6 0.21 nM for euthyroid and 3.04 6 0.77 nM (P , 0.001) for hyperthyroid mice. Treatment with Scl-Ab and ZOL reduced serum T4 concentrations in hyperthyroid mice by 20% (P , 0.01) and 12% (P , 0.05) respectively, whereas T3 concentrations were not significantly changed by the treatments.
Bone volume is reduced by hyperthyroidism and restored through both sclerostin blockade and ZOL treatment
In line with our previous results (17), continuous T4 treatment reduced trabecular bone volume and deteriorated trabecular structure at the spine and femur [ Fig. 1(a-f) ]. At the spine, continuous T4 treatment led to a 42% reduction in trabecular bone volume fraction (P , 0.05) and a 35% reduction in trabecular BMD (P , 0.05). Scl-Ab treatment of hyperthyroid mice increased bone volume 2.8-fold (P , 0.001) and BMD 2.2-fold (P , 0.001), whereas treatment with ZOL led to a 1.9-fold increase in bone volume (P , 0.01) and a 1.6-fold increase in BMD (P , 0.01). In euthyroid mice, Scl-Ab treatment led to a 2.7-fold increase in bone volume and a 2.2-fold increase in BMD (both P , 0.001), whereas treatment with ZOL led to a 1.6-fold increase in bone volume and a 1.4-fold increase in BMD (P , 0.05) [ Fig. 1(a) ]. At the distal femur, hyperthyroid mice also depicted a reduced trabecular bone volume (255%, P , 0.05) and BMD (247%, P , 0.05) as compared with euthyroid mice. Scl-Ab treatment of hyperthyroid mice increased the distal femur bone volume fraction 3.7-fold (P , 0.001) and the BMD 2.8-fold (P , 0.001), whereas treatment with ZOL induced a 2.5-fold increase of bone volume (P , 0.01) and a 2.2-fold increase of BMD (P , 0.001). In euthyroid mice, Scl-Ab treatment led to 3.4-fold increase in trabecular volume and a 2.6-fold increase in BMD (both P , 0.001), whereas treatment with ZOL did not affect trabecular bone volume or BMD [ Fig. 1(d)] .
The SMI at the spine of euthyroid mice was 1.78 6 0.53 and shifted up to 2.40 6 0.32 in hyperthyroid mice, indicating more rod-like-structured trabeculae. Treatment of hyperthyroid mice with Scl-Ab reduced the SMI at the spine to 1.02 6 0.47 and treatment with ZOL to 1.38 6 0.24, whereas in euthyroid mice Scl-Ab treatment reduced the SMI at the spine to 0.342 6 0.22 and treatment with ZOL to 0.821 6 0.54, indicating a shift to a plate-like structure through both treatments [ Fig. 1(b) ]. Similar trends were seen at the femur [ Fig. 1(e) ]. Further analysis of trabecular indices underscored the changes in the structure of trabecular bone. Hyperthyroid mice displayed a reduced number (226%, P , 0.001) and an increased separation (+36%, P , 0.001) of trabeculae at the femur when compared with euthyroid mice, whereas no significant difference was detected in trabecular thickness. Hyperthyroid mice treated with Scl-Ab also depicted a 35% increase (P , 0.001) in trabecular number and a 23% reduction in trabecular separation (P , 0.001), whereas ZOL treatment led to a 45% increase (P , 0.001) in trabecular number and a 29% decrease (P , 0.001) in trabecular separation. In euthyroid mice, Scl-Ab treatment led to an 86% increase in trabecular thickness (P , 0.001), a 21% increase in trabecular number (P , 0.05), and a 25% decrease in trabecular separation (P , 0.05), whereas ZOL treatment led to a 21% increase in trabecular thickness (P , 0.05), an 18% increase in trabecular number (P , 0.05), and a 22% decrease in trabecular separation, with the latter not reaching statistical significance [ Fig. 1(f) ].
Changes in the cortical bone compartment were not as pronounced as in trabecular bone, with hyperthyroid mice showing a trend toward lower cortical thickness measured at the femoral midshaft (212%, P = 0.08), which did not reach statistical significance. Treatment of hyperthyroid mice with Scl-Ab led to a 30% increase in cortical thickness (P , 0.01), whereas a 14% increase was noted through ZOL, with the latter not being statistically significant. Cortical bone density was not affected (data not shown).
Thus, these data show that hyperthyroidism pharmacologically induced at adult age reduces trabecular bone mass and that both treatment regimens restore bone mass in hyperthyroidism in mice.
Bone strength is reduced by hyperthyroidism and restored through both sclerostin blockade and ZOL treatment Reference-point indentation was performed to gain insight into bone stiffness and hardness at tissue level ( Table 1 ). The total indentation distance refers to the distance between the initial touchdown of the probe and the maximum indentation achieved at the last cycle and was, as expected, increased in hyperthyroid mice as compared with euthyroid controls (+10%). Treatments with Scl-Ab and ZOL decreased the total indentation distance to that of euthyroid controls (both P , 0.05). The first cycle touchdown distance, as a measure of bone flexibility, was also increased in hyperthyroid mice as compared with euthyroid controls (+44%, P , 0.05). SclAb treatment of hyperthyroid mice led to a 30% reduction (P , 0.05), whereas treatment with ZOL reduced this parameter by 26%, with the latter not reaching statistical significance. Other reference point indentation parameters are shown in Table 1 .
To analyze overall bone strength, we performed virtual and actual biomechanical testing. Trabecular bone stiffness estimated using micro-CT-based finite element modeling of a compression test of the lumbar vertebrae was 63% lower in hyperthyroid mice and was 3.8-fold greater (P , 0.05) after Scl-Ab and 2.7-fold greater after ZOL treatment, although the latter did not reach statistical significance. In euthyroid mice, treatment with Scl-Ab led to a 4.4-fold increase (P , 0.001) in trabecular bone stiffness at the spine, and ZOL to a 1.9-fold increase, with the latter not reaching statistical significance [ Fig. 2(a) ]. The 3-point bending test further revealed trends toward reduction (10% in ultimate load, 28% in energy to failure, and 8% in stiffness at the femoral midshaft in hyperthyroid mice) [ Fig. 2(b-d) ]. Treatment of hyperthyroid mice with Scl-Ab increased stiffness 1.5-fold (P , 0.001) [ Fig. 2(b) ], ultimate load twofold (P , 0.001) [ Fig. 2(c) ], and energy to failure threefold (P , 0.001) [ Fig. 2(d) ] compared with vehicle. Treatment of hyperthyroid mice with ZOL led to smaller increases in mechanical properties with a 22% increase in ultimate load (P , 0.001) [ Fig. 2(c) ] and a 72% increase in energy to failure, with the latter not statistically significant [ Fig. 2(d) ]. In euthyroid mice, treatment with Scl-Ab led to a 75% increase in stiffness, a 71% increase in ultimate load, and a twofold increase in energy to failure (all P , 0.001), whereas treatment with ZOL did not significantly affect these parameters [ Fig. 2(b-d)] .
Thus, both treatment modalities restore biomechanical bone properties, which are compromised in hyperthyroid mice.
Bone resorption is increased in hyperthyroidism and suppressed through treatment with Scl-Ab and ZOL
Histology was used to determine the number of osteoclasts and obtain more insight into the effects of the disease and treatments on bone resorption. Using TRAP staining, a larger osteoclast surface and a higher number of osteoclasts per bone perimeter were detected in the vertebral trabecular bone of hyperthyroid mice [ Fig. 3(a)  and 3(b) ]. Consistent with this, a twofold increase in these osteoclast parameters was found in the distal femur of hyperthyroid mice (data not shown). Treatment of hyperthyroid mice with Scl-Ab reduced osteoclast surface per bone surface by 47% (P , 0.001) and treatment with ZOL by 29% at the spine, whereas in euthyroid animals Scl-Ab and ZOL had no significant effect [ Fig. 3(a) ]. Moreover, a twofold reduction in number of osteoclasts per bone perimeter was observed through treatment of hyperthyroid mice with Scl-Ab and ZOL (both P , 0.001). In euthyroid mice, Scl-Ab treatment reduced the number of osteoclasts per bone perimeter by 55% (P , 0.05) and ZOL by 33%, with the latter not being statistically significant [ Fig. 3(b) ]. Interestingly, the number of osteoclasts per bone perimeter was also highly significantly suppressed by ZOL in hyperthyroid mice in the femur, but not by Scl-Ab, suggesting site-specific effects of sclerostin inhibition (data not shown). Finally, the serum marker of bone resorption CTX was increased in hyperthyroid mice compared with euthyroid controls (+47%, P , 0.01) and decreased in hyperthyroid mice through treatment with ZOL (230%, P , 0.01), but not with Scl-Ab. In euthyroid mice, no change in CTX concentrations was noted through Scl-Ab or ZOL treatment [ Fig. 3(d) ].
Hyperthyroidism-induced bone formation is suppressed through treatment with ZOL but not through sclerostin blockade
Dynamic bone histomorphometry revealed a 60% increase of mineralizing surface per bone surface in the vertebral body of hyperthyroid mice [ Fig. 4(a) ]. Treatment of hyperthyroid mice with ZOL led to a decrease of the mineralizing surface by 48%, whereas treatment with Scl-Ab did not have this effect. In euthyroid animals, SclAb treatment increased mineralizing surface by 2.7-fold (P , 0.001), an effect not seen by ZOL [ Fig. 4(a) ]. Additionally, the mineral apposition rate (+20%) was also increased in hyperthyroid mice, leading to a higher bone formation rate (+90%) [Fig. 4(b) and 4(c) ]. Treatment of hyperthyroid mice with ZOL induced a potent suppression of bone formation as depicted by a 62% reduction in mineral apposition rate (P , 0.001) and a 76% reduction in bone formation rate (P , 0.01), effects that were not observed through treatment with Scl-Ab [ Fig.  4(b) and 4(c) ]. In euthyroid animals, treatment with SclAb led to 37% increase in mineral apposition rate and to a 3.3-fold increase in bone formation rate (P , 0.001) [ Fig. 4 (b) and 4(c)]. ZOL had no effect on bone formation in euthyroid mice [ Fig. 4(b) and 4(c) ]. Congruent with these data, serum concentration of bone formation markers P1NP and OCN were increased in hyperthyroid mice (2.3-fold, P , 0.001 for P1NP and 1.5-fold, P , 0.01 for OCN). Treatment of hyperthyroid mice with ZOL reduced OCN by 28% (P , 0.05) and P1NP by 25%, although the latter did not reach statistical significance, whereas treatment with Scl-Ab did not influence bone formation markers in hyperthyroid mice. In euthyroid mice, treatment with ZOL had no effect on bone formation markers, whereas treatment with SclAb led to a 59% increase in OCN (P , 0.05), with no significant increase in P1NP [ Fig. 4 (e) and 4(f)]. Levels of the Wnt inhibitor DKK-1 were reduced in hyperthyroidism by 32% (P , 0.05), as has been previously published (17) . In hyperthyroid mice, ZOL treatment did not affect DKK-1 concentrations whereas Scl-Ab led to a 43% increase of DKK-1 levels; a similar trend was noted in euthyroid counterparts [ Fig. 4(g) ]. As reported previously (17) , serum sclerostin concentrations increased in hyperthyroidism. ZOL treatment did not alter sclerostin levels [ Fig. 4(h) ]. We could not measure sclerostin in the serum of mice treated with the Scl-Ab, as the antibody interferes with the assay [Fig. 4(h) ].
Sclerostin blockade and ZOL treatment differentially influence bone mineralization density distribution in hyperthyroid mice
Comparison between hyperthyroid mice and euthyroid controls revealed higher Ca Low (+30%, P , 0.01) in hyperthyroid mice, whereas all other BMDD parameters were not significantly different [ Fig. 5(a-e) ]. Treatment of hyperthyroid mice with Scl-Ab caused a significant reduction of Ca Low (236%, P , 0.001) and no other changes vs untreated hyperthyroid mice [ Fig. 5(a-e) ]. Treatment of Taken together, these data show that hyperthyroidism leads to an increased proportion of low-mineralized bone, which can be restored by bone-forming and antiresorptive therapies.
Discussion
Hyperthyroidism in mice causes a reduction in trabecular bone volume and an increase in bone turnover (17) .
Although bone formation is also upregulated (17), the accelerated resorption dominates, mimicking a state of high-turnover osteoporosis (27) . A similar mechanism occurs in postmenopausal osteoporosis where estrogen reduction triggers excessive bone resorption and results in a phase of rapid bone loss (28) . In contrast, glucocorticoid-induced osteoporosis is characterized by an early phase of transiently increased bone resorption and a subsequent sustained phase of suppressed bone formation (29) . These distinct mechanisms of bone disease underline the need for individualized pharmacological interventions. In this study, we investigate the effects of two different therapeutic modalities-an antiresorptive and a bone-forming agent-on bone architecture, material, and biomechanical properties in a murine model of pharmacologically induced hyperthyroidism, based on the following rationale. Whereas the antiresorptive bisphosphonate is expected to inhibit bone resorption (and formation), the sclerostin antibody is expected to neutralize the hyperthyroidism-induced increase in sclerostin and further increase bone formation (17) .
Micro-CT analysis revealed that, as was expected, both treatments led to further increases in trabecular bone volume and BMD in euthyroid mice. Furthermore, both treatments ameliorated the reduction in trabecular bone volume fraction and BMD induced by hyperthyroidism at the axial and the appendicular skeleton. However, compared with the euthyroid treatment controls, it appears that neither treatment can fully reverse the underlying mechanisms to completely prevent hyperthyroidism-induced bone loss. Of note, the effects of hyperthyroidism per se were more pronounced on trabecular than cortical bone, which may underline the fact that trabecular bone is the major skeletal compartment under endocrine control. The only cortical parameter modulated through treatment with Scl-Ab was cortical thickness, which may underscore the effect of SclAb on bone modeling. Previous studies in male cynomolgus monkeys and ovariectomized rats have shown that Scl-Ab treatment dose-dependently increases modeling-based bone formation at the periosteal and endocortical surfaces (30, 31) .
To gain more insight into the distinctive mechanisms of action of both agents, dynamic histomorphometry was performed. It is a well-established fact that bisphosphonates severely impair osteoclast function (32) , which was also the case in our study. An interesting finding was the suppression of osteoclast numbers in the vertebral body, but not the femur, through Scl-Ab in hyperthyroidism. The suppression of bone resorption is in line with previous data showing that the humanized Scl-Ab romosozumab transiently decreases bone resorption markers in humans (19, 20) . With regard to animal studies, the data are inconsistent. In vitro studies have shown that osteoclasts are indirectly stimulated by sclerostin in a receptor activator of nuclear factor kBligand-mediated manner (33) . In ovariectomized rats, serum tartrate-resistant acid phosphatase type 5b, which is indicative of osteoclast number, was decreased at week 6 but not at week 26 of Scl-Ab treatment (34) . Similarly, osteoclast numbers assessed via histomorphometry were decreased in ovariectomized aged rats during Scl-Ab treatment, whereas after treatment cessation, osteoclast numbers increased (35) . In adolescent female cynomolgus monkeys, CTX concentrations were not affected by SclAb treatment (30) , an observation we also made in our study and could be due to the treatment duration. Also in the context of glucocorticoid-induced osteoporosis in mice, Scl-Ab treatment reduced markers of bone resorption in two studies (36, 37) , suggesting that sclerostin might regulate bone resorption independently of its action on bone formation (38) . This observation, however, could not be reproduced in a model of glucocorticoidtreated rats (39) . Overall, the evidence indicates that inhibition of sclerostin suppresses bone resorption, which is beneficial to counteract the high bone resorption in hyperthyroidism.
Regarding bone formation, treatment with ZOL led to a pronounced reduction in the bone formation rate as well as to a suppression of serum bone formation markers, which is consistent with the known mode of Representative calcein double labeling of the third vertebral body from 3-month-old C57BL/6 mice treated with PBS, Scl-Ab, or ZOL. Scale bars, 100 mm. Serum concentrations of (e) P1NP, (f) OCN, (g) DKK-1, and (h) sclerostin as determined using an ELISA. n = 10 for euthyroid mice treated with PBS, hyperthyroid mice treated with PBS, hyperthyroid mice treated with Scl-Ab, and hyperthyroid mice treated with ZOL mice. *P # 0.05, **P # 0.01, ***P # 0.001 between euthyroid and hyperthyroid mice; # P # 0.05, ## P # 0.01, ### P # 0.001 between hyperthyroid mice treated with PBS and hyperthyroid mice treated with Scl-Ab or ZOL, respectively; action of this antiresorptive agent. Scl-Ab, alternatively, did not suppress bone formation, congruent with its role as an osteoanabolic agent, but also failed to significantly further enhance bone formation. This could be due to the fact that bone formation is already high in the hyperthyroid state as opposed to euthyroidism where a significant increase of OCN through Scl-Ab treatment was noted. Thus, as opposed to diseases with a profound suppression of bone formation, such as glucocorticoid-induced osteoporosis, in which Scl-Ab treatment has a potent osteoanabolic effect, bone formation already seems to be maximally activated in hyperthyroidism, leaving no room for further induction, even using potent bone-forming agents. In fact, this phenomenon of self-regulation of bone formation has been described in various animal models. An in vitro study investigating the time-dependent effect of Scl-Ab on the osteoblast lineage cells in rats showed time-dependent reductions in subpopulations of the osteoblast lineage in the vertrebra (40) . Furthermore, ovariectomized rats treated with Scl-Ab depicted increased SOST and DKK1 expression (34) , and SOST deficiency results in a compensatory DKK-1 overexpression (41), thus limiting an excessive bone gain. In our model, we could not measure sclerostin in the serum of mice treated with the Scl-Ab, as the antibody interferes with the assay. DKK-1 serum concentrations were not affected by ZOL but upregulated in Scl-Ab-treated hyperthyroid mice. Alternatively, the self-regulatory effect in bone formation could be partly due to the upregulation of other Wnt inhibitors as, for example, secreted frizzledrelated proteins (42) .
To gain insight into the biomechanical properties of hyperthyroid-induced bone disease, the 3-point bending test and reference point indentation were performed. To our knowledge, this is the first study to investigate the effects of an antiresorptive and osteoanabolic treatment on bone stiffness and strength in the setting of hyperthyroidism. Both treatments increased estimated bone stiffness at the lumbar vertebrae and ultimate bending load at the femoral diaphysis, with Scl-Ab having the more pronounced effect. To date, there are several different studies examining the effect of treatment with either Scl-Ab or ZOL on bone strength in ovariectomized rats (31, 43) , although the different experimental designs of these studies do not allow for a direct comparison. Because the bone composition critically contributes to bone strength, we performed quantitative backscatter electron imaging analyses to gain information on bone mineralization. The differences between hyperthyroid vs control animals indicate that hyperthyroidism is associated with an increased fraction of low mineralized bone, consistent with the increased rate of bone remodeling. This change is in line with the increase in total indentation distance and first cycle touchdown distance by reference point indentation, showing that the probe can penetrate hyperthyroid bone deeper, likely due to its greater percentage of low mineralized bone. Treatment of hyperthyroid mice with Scl-Ab did not alter average bone matrix mineralization, whereas treatment with ZOL increased average matrix mineralization in hyperthyroid mice. Interestingly, both treatment modalities decreased the percentage of low mineralized bone areas, though probably through different mechanisms. Scl-Ab increased bone volume and trabecular thickness, which consequently reduced the percentage value of low mineralized bone areas. A reduction in Ca Low through Scl-Ab treatment has also been previously observed in trabecular bone of wild-type mice (44) . In contrast, ZOL treatment led to a suppression of bone turnover, thus leading to a general decrease in the amount of newly formed bone and thus low mineralized bone areas. This constitutes a wellknown effect of antiresorptive drugs on bone matrix mineralization in the setting of postmenopausal osteoporosis (45, 46) .
Despite its strengths, our study has potential limitations. First, it cannot be ruled out that the treatments with Scl-Ab or ZOL per se could have a subtle influence on the thyroid status, which is in line with our data for T4 concentrations and has also been reported in humans (47) . Second, the state of hyperthyroidism was only maintained for 4 weeks, which might be too short to mimic chronic hyperthyroidism in humans, and the treatments with either Scl-Ab or ZOL were implemented concomitantly, which may not fully reflect the clinical scenario in humans. Third, we elected to use only male mice to avoid sex steroid fluctuations during the estrous cycle, which could affect the thyroid status. Nonetheless, the mouse model used for pharmacologically induced hyperthyroidism does reflect the fundamental changes in bone turnover and BMD as found in humans.
In conclusion, our study shows that Scl-Ab and ZOL both improved bone mass and quality in hyperthyroidisminduced bone disease in mice, yet via different effects on bone turnover. More extensive studies are warranted to unravel the long-term effects of these agents and to investigate whether these pharmacological interventions can be used in human hyperthyroidism-induced bone disease.
